A1選択性アデノシンアナログによる静脈内予行治療は,心臓を心臓発作から保護する

J D Thornton¹, G S Liu, R A Olsson

¹Department of Physiology, University of South Alabama, Mobile 36688.

Circulation

|February 1, 1992

まとめ

PIAやCCPAのようなアデノシンA1受容体アゴニストの静脈内投与は,心臓を心臓発作から守ります. この心臓の保護は,アゴニストが再注射中にではなく,イシュケミアの前に投与されたときに達成されます.

科学分野:

心血管科学の研究について
薬理学薬理学とは
発血不全の予備条件付け

背景:

アデノシン前治療は,A1受容体を通して心臓を心臓発作から保護します.
前回のアデノシン投与が冠動脈循環に制限された全身性低血圧.

研究の目的:

A1選択性アデノシンアゴニストの静脈内投与により,心臓の保護が達成できるかどうかを調査する.
免疫不全前におけるA1受容体の活性化が保護のために必要かどうかを判断する.

主な方法:

胸開きで麻酔を受けたウサギは,地域冠動脈不血症と再注射を受けた.
心臓発作の大きさはテトラゾリウム染色を用いて測定した.
A1選択性アゴニスト (PIA,CCPA) とA2選択性アゴニスト (CGS 21680) は,イシュケミアの前に静脈内投与された.

主要な成果:

静脈内投与のN6-(フェニル-2R-イソプロピル) -アデノシン (PIA) と2-クロロ-N6-サイクロペンチラデノシン (CCPA) は,イシュケミア前に投与された場合,心臓発作のサイズを著しく制限しました.
再注射中のPIAの投与は,保護を提供しなかった.
A2受容体アゴニストであるCGS 21680は,心臓発作のサイズを制限できませんでした.
保護は,ウサギが歩行させられた場合でも観察され,ブラジカルディアをメカニズムとして排除しました.

結論:

アデノシンA1受容体の刺激により,心不全に対する抵抗性が生じます.
心臓発作に対する心臓の保護は,A1選択性アデノシン剤の静脈内投与によって達成できます.

さらに関連する動画

10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

07:58

Induction and Assessment of Ischemia-reperfusion Injury in Langendorff-perfused Rat Hearts

Published on: July 27, 2015

関連する概念動画

01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

関連する実験動画